Clinical trials: COPD Exacerbation Acute
Chronic Obstructive Pulmonary Disease
An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway.
- Trial name
- NCT03207776
- Testing
- Usual Care, COPD Clinical Pathway
- Where
- 8 sites in United States
- Volunteers
- 4,832 people
- Sponsor
- Wake Forest University Health Sciences
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Obstructive Pulmonary Disease
Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine the effectiveness of antibiotic therapy for patients with acute exacerbations of mild-to-moderate chronic obstructive pulmonary disease.
- Trial name
- TRANCE (NCT00495586)
- Testing
- Amoxicillin and clavulanic acid
- Where
- 13 sites in Spain
- Volunteers
- 318 people
- Sponsor
- Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)
COPD Exacerbation
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
The primary objective of the study is to determine the percentage of patients with "therapeutic success" at the end of the cycle of antibiotic therapy (10 days), in the two treatment groups (levofloxacin and prulifloxacin).
- Trial name
- FLOR (NCT01710488)
- Testing
- Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day
- Where
- 25 sites in Italy
- Volunteers
- 258 people
- Sponsor
- Fadoi Foundation, Italy
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an…
- Trial name
- NCT00739648
- Testing
- MP-376
- Where
- 39 sites in United States
- Volunteers
- 322 people
- Sponsor
- Amgen
Pneumococcal Infections, COPD
Immunization To Prevent Acute COPD Exacerbations
Prospective multicenter observational study, to evaluate the impact of routine clinical practice vaccination with PCV13 on the reduction of the risk of moderate/severe COPD exacerbations
- Trial name
- NCT03276754
- Where
- 11 sites in Spain
- Volunteers
- 530 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01663987
- Testing
- tiotropium bromide
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Effect of Blood Flow Restriction Resistance Exercises in COPDAE In-patient Rehabilitation
This is a randomised controlled trial of the blood flow restriction resistance exercise (BFR-RE) for early rehabilitation of chronic obstructive pulmonary disease acute exacerbation (COPDAE) in the Haven of Hope Hospital.
- Trial name
- NCT04448236
- Testing
- Blood flow restriction resistance exercise
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Hospital Authority, Hong Kong
Chronic Obstructive Pulmonary Disease
Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD
This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03094806
- Testing
- Acapella Vibratory PEP Therapy Device plus usual care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial
The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics…
- Trial name
- NCT00789997
- Testing
- Prednisone, Etanercept, levofloxacin
- Volunteers
- 81 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Obstructive Pulmonary Disease
A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications
This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI.
- Trial name
- NCT04353661
- Testing
- Azithromycin, HP xenon (¹²⁹XE)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Genentech, Inc.
COPD, COPD Exacerbation Acute
ProAir Digihaler in COPD Disease Management: A Real World Study
A pilot study to explore the utilization of the TEVA ProAir Digihaler rescue medication use and inhalation parameters to identify disease deterioration to help in the management of COPD patients in clinical practice.
- Trial name
- NCT04821869
- Testing
- ProAir Digihaler, Digihaler
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
Chronic Obstructive Pulmonary Disease COPD
A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
- Trial name
- NCT02238483
- Testing
- AZD7624 1.0 mg
- Where
- 41 sites in United States, Argentina and 4 more
- Volunteers
- 213 people
- Sponsor
- AstraZeneca
COPD Exacerbation Acute
Treatment of Pneumocystis in COPD (the TOPIC Study)
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease associated with chronic inflammation in the airways and lung, resulting in significant morbidity and mortality worldwide.
- Trial name
- NCT05418777
- Testing
- Trimethoprim Sulfamethoxazole
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Corewell Health East
COPD, COPD Exacerbation
Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, and over 90% of COPD-related deaths occurring in low- and middle-income countries (LMICs).
- Conditions
- COPD, COPD Exacerbation, COPD Exacerbation Acute, Pollution Related Respiratory Disorder
- Trial name
- NCT03984188
- Testing
- Theophylline ER, Standard of Care Treatment
- Where
- 2 sites in Uganda
- Volunteers
- 100 people
- Sponsor
- University of Miami